Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
771.120.17%
QQQ
716.510.11%
BTC/USD
64534.740.0986%
DIA
543.750.17%
GLD
392.420.71%
TLT
83.050.06%

Nektar Therapeutics

NKTRNASDAQ
Trade with Public
Trade with Public
$73.09
0.330.45%
At close: Aug 5, 5:00 PM EST
$71.79
-1.30-1.78%
After Hours: 6:55 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Nektar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nektar Therapeutics (NKTR).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

9Buy
2Hold
1Sell
Consensus RatingBuy# Analysts12Avg. Consensus PT$111Upside to Avg. PT+55.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 22, 2026Canaccord GenuityEdward NashInitiateBuy$153
May 11, 2026WedbushMartin Fan PT CutNeutral$95→$80
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153

Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.
Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $95 to $80.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192

Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151

Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $123 to $151.
Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $185

HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $165 to $185.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved